Table 4.
Effects of benzodiazepine site ligands of differing intrinsic efficacies on GABA-mediated modulation of [35S]TBPS binding in rat and human postmortem cortex and cerebellum membranes
IC50, μM |
||||
---|---|---|---|---|
Human |
Rat |
|||
Cortex | Cerebellum | Cortex | Cerebellum | |
Control | 0.90±0.07 | 0.65±0.11 | 1.13±0.15 | 0.90±0.08 |
Diazepam | 0.43±0.04* | 0.33±0.10* | 0.56±0.03* | 0.48±0.03* |
Ro15-1788 | 0.74±0.05 | 0.65±0.06 | 1.05±0.01 | 0.88±0.08 |
DMCM | 2.29±0.38* | 1.42±0.31* | 1.91±0.04* | 2.54±0.11* |
Abbreviations: ANOVA, analysis of variance; DMCM, methyl-6,7-dimethoxy-4-ethyl-β-carboline-3-carboxylate; GABA, γ-aminobutyric acid; [35S]TBPS, [35S]t-butylbicyclophosphorothionate.
Data shown are mean±s.e.m. (n=3–4). Statistical differences between groups were evaluated using a one-way ANOVA with post hoc Dunnett's multiple comparison tests for each radioligand. (*P<0.05).